arrow_back Back to App

New Education Program on Biosimilar Drugs for Patients and Doctors.

This law aims to boost knowledge among doctors, patients, and caregivers about biological drugs, especially biosimilars, which are often cheaper alternatives. The government will create a dedicated website and educational programs to explain what these products are and how they are approved. Increased understanding of biosimilars can lead to greater treatment access and potentially lower medication costs for citizens.
Key points
Establishment of an official government website providing educational materials on biological products for the public and healthcare providers.
Requirement to explain key terms (e.g., "biosimilar," "interchangeable") and the standards for drug approval, building confidence in cheaper options.
Development of continuing education programs for healthcare providers regarding the safe prescribing and clinical use of biosimilars.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_1873
Sponsor: Rep. Bucshon, Larry [R-IN-8]
Process start date: 2021-03-12
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Advancing Education on Biosimilars Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_1873.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-03-12.

What are the main provisions?

Key points include:

  • Establishment of an official government website providing educational materials on biological products for the public and healthcare providers.
  • Requirement to explain key terms (e.g., "biosimilar," "interchangeable") and the standards for drug approval, building confidence in cheaper options.
  • Development of continuing education programs for healthcare providers regarding the safe prescribing and clinical use of biosimilars.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Bucshon, Larry [R-IN-8].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

CATEGORIES

Health